Cancer Diagnostics Market to Reach US$ 292.4 Bn by 2035 as AI, Liquid Biopsy and Precision Medicine Reshape Early Detection

Cancer diagnostics covers the identification, detection, confirmation, staging, and monitoring of cancer using imaging, laboratory, pathology, molecular, and genetic tests. It combines CT, MRI, PET, ultrasound, endoscopy, biopsy, biomarkers, NGS, liquid biopsy, immunoassays, and digital pathology.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3637

Market Overview

The cancer diagnostics industry was valued at US$ 121.8 Bn in 2024 and is expected to grow at a moderate 8.4% CAGR between 2025 and 2035, crossing US$ 292.4 Bn by 2035. Growth reflects demand for earlier diagnosis, cancer classification, treatment selection, recurrence monitoring, and response assessment.

Imaging techniques remain important for tumor detection, staging, and treatment monitoring. Biopsy provides definitive pathological and molecular information, while liquid biopsy can reduce invasiveness and support repeated monitoring.

Key Drivers of Market Growth

Technological advancements are a major growth engine. NGS, digital pathology, AI-assisted imaging, molecular diagnostics, and liquid biopsy are improving the speed, precision, and information available from cancer testing. AI is also helping laboratories and pathologists extract additional insights from digital tissue images.

For example, Owkin announced MSIntuit CRC v2 in October 2024, an AI solution designed to support microsatellite instability testing in colorectal cancer. The research-use-only version was planned for Roche’s navify Digital Pathology platform in the U.S., illustrating the growing convergence of AI, pathology, and precision oncology.

Increasing awareness and early detection are another major driver. Public education, screening programs, and wider access to diagnostics are encouraging earlier evaluation. Earlier diagnosis can expand treatment options and support more targeted interventions.

Government initiatives, cancer-control programs, research funding, and expanding precision-medicine strategies also support demand.

Key Players and Industry Leaders

Major participants include Cancer Diagnostics, Inc., Abbott, Bio-Rad Laboratories, GE HealthCare, Thermo Fisher Scientific, F. Hoffmann-La Roche, Quest Diagnostics, QIAGEN, Siemens Healthineers, MedGenome, and Biodesix.

Competition centers on accuracy, workflow integration, automation, biomarker discovery, validation, and partnerships. Companies are investing in molecular platforms, digital pathology, companion diagnostics, liquid biopsy, and AI-enabled solutions.

Recent collaborations demonstrate this direction. In August 2024, Hitachi High-Tech and Gencurix announced a strategic partnership combining in-vitro diagnostics and digital technology with biomarker discovery and molecular testing expertise, with plans to develop cancer molecular diagnostic testing services.

Key Trends for the Future

A defining trend will be the movement toward minimally invasive and information-rich testing. Liquid biopsy, circulating tumor DNA, circulating nucleosomes, and other biomarkers could support earlier detection, treatment selection, minimal residual disease assessment, and recurrence monitoring.

AI-enabled pathology and imaging will also expand. Digital pathology is likely to become increasingly connected with molecular data and electronic clinical workflows.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/cancer-diagnostics-market.html

New Opportunities and Challenges

The strongest opportunities lie in pan-cancer screening, biomarker-based diagnostics, decentralized testing, at-home sampling, companion diagnostics, and integrated diagnostic platforms. Emerging markets may offer significant potential as healthcare infrastructure, cancer awareness, and diagnostic capacity expand.

Liquid biopsy is a particularly active innovation area. In March 2025, Volition reported that its Nu.Q Cancer immunoassay under development detected a range of 21 cancers in a study, highlighting interest in blood-based multi-cancer approaches. The finding remains under development and validation.

Challenges include costs, reimbursement limitations, regulatory requirements, clinical validation, data privacy, and uneven access to specialist diagnostic centers. In lower-resource settings, shortages of trained professionals and laboratory infrastructure can further restrict adoption.

Market Trends & Innovations

Innovation is shifting toward integrated platforms that combine imaging, pathology, genomics, biomarkers, and AI. NGS is enabling broader molecular profiling, while digital pathology supports scalable image-based analysis. Liquid biopsy is developing beyond early detection toward therapy monitoring and residual disease assessment.

Partnerships among diagnostic companies, technology providers, hospitals, pharmaceutical companies, and biotechnology firms are likely to increase.

Future Outlook

The market is positioned for sustained expansion through 2035, with revenue projected to exceed US$ 292.4 Bn. North America is expected to remain a leading regional market because of advanced healthcare infrastructure, R&D investment, technology adoption, and established diagnostic networks. Asia Pacific offers long-term opportunity as healthcare investment, awareness, and diagnostic capacity increase.

Market Segmentation

By Type of Cancer Diagnostics: Tumor Biomarker Tests, Imaging Techniques, Endoscopy, Biopsy, Immunoassays, and Others.

By Product Type: Instruments; Assay Kits & Reagents.

By Application: Lung, Breast, Colorectal, Prostate, Liver, Ovarian, Kidney, Pancreatic, Blood, and Other Cancers.

By End-user: Hospitals, Diagnostic Centers, At-home Settings, and Others.

By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=3637<ype=S

Important FAQs with Answers

Q1. What was the cancer diagnostics market size in 2024?

A. The market was valued at US$ 121.8 Bn in 2024.

Q2. What will the market size be in 2035?

A. It is projected to cross US$ 292.4 Bn by 2035.

Q3. What is the expected CAGR?

A. The market is projected to grow at an 8.4% CAGR from 2025 to 2035.

Q4. What is driving market growth?

A. Rising cancer incidence, early-detection demand, AI, liquid biopsy, molecular diagnostics, precision medicine, and healthcare investment are major drivers.

Q5. What are the main challenges?

A. High costs, reimbursement constraints, regulatory hurdles, clinical-validation requirements, and unequal diagnostic access remain significant barriers.

More Trending Reports by Transparency Market Research –

Spine Surgery Products Market: https://www.transparencymarketresearch.com/spine-surgery-products-market.html

Ostomy Dressing Market: https://www.transparencymarketresearch.com/ostomy-dressing-market.html

Healthcare Interoperability Solutions Market: https://www.transparencymarketresearch.com/healthcare-interoperability-solutions-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com